

Botswana Country Operational Plan FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Gaimmary or rial	ountrial y of Flatined Funding by Agency and Funding Source					
		Funding Source	Funding Source			
Agency	GAP	GHP-State	GHP-USAID	Total	Applied Pipeline	
DOD				0	1,095,000	
HHS/CDC	2,196,250	13,097,432		15,293,682	6,986,327	
HHS/HRSA		3,325,000		3,325,000	0	
PC	0	1,850,091	0	1,850,091	500,000	
State		185,915		185,915	0	
State/AF		225,000		225,000	0	
USAID		18,083,985		18,083,985	455,000	
Total	2,196,250	36,767,423	0	38,963,673	9,036,327	

Summary of Planned Funding by Budget Code and Agency

		_		Agency					
Budget Code	State	DOD	HHS/CDC	HHS/HRS A	PC	State/AF	USAID	On Hold Amount	Total
CIRC		0	359,399					0	359,399
НВНС			1,844,387	600,000			5,955,000	0	8,399,387
HKID			2,773				3,365,546	0	3,368,319
HLAB		0	252,637	375,000		0	0	0	627,637
HMBL			66,626			0		0	66,626
HMIN			0					0	0
HTXD			205,550				0	0	205,550
HTXS			2,981,234	900,000		0	927,783	0	4,809,017
HVAB			0				61,113	0	61,113
HVCT		0	604,392	650,000			350,000	0	1,604,392
HVMS	185,915	0	5,223,858		1,730,091		1,918,036	0	9,057,900
HVOP		0	200,413	0	120,000		2,017,742	0	2,338,155
HVSI			601,999	100,000			85,559	0	787,558



	185,915	0 15 2	93,682	3,325,000	1,850,091	225 000	18,083,985	0	38,963,673
PDTX		4	53,875					0	453,875
PDCS		4	47,211				1,385,559	0	1,832,770
OHSS			21,099	0		225,000	517,647	0	763,746
мтст			81,064	0				0	81,064
HVTB		1,9	47,165	700,000			1,500,000	0	4,147,165



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	8,300,000	0
HKID	3,243,317	0
HVTB	4,050,000	0
PDCS	1,730,000	0
Total Technical Area Planned Funding:	17,323,317	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	375,000	0
HVSI	300,000	0
OHSS	225,000	0
Total Technical Area Planned Funding:	900,000	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	280,000	0
HMBL	0	0
HMIN	0	0
HVAB	0	0
нуст	1,510,000	0
HVOP	2,152,037	0
мтст	0	0
Total Technical Area Planned	3,942,037	0



Funding:	
----------	--

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	200,000	0
HTXS	4,659,042	0
PDTX	430,000	0
Total Technical Area Planned	E 200 042	
Funding:	5,289,042	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		70
	Number of new ANC and L&D clients		70
	By: Known positives at entry		16
PMTCT_STAT_DSD	By: Number of new positives identified		0
	Sum of Positives Status disaggregates		16
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		



	Degrated and the DDE ANAC		
	Required only for DREAMS		
	Countries - By Number of		
	known positives: <15		
	Required only for DREAMS		
	Countries - By Number of		
	known positives: 15-19		
	Required only for DREAMS		
	Countries - By Number of		
	known positives: 20-24		
	Required only for DREAMS		
	Countries - By Number of		
	known positives: 25+		
	Required only for DREAMS		
	Countries - Denominator:		
	<15		
	Required only for DREAMS Countries - Denominator:		
	<15-19		
	Required only for DREAMS		
	Countries - Denominator:		
	20-24		
	Required only for DREAMS		
	Countries - Denominator:		
	25+		
	PMTCT_STAT_TA Number		
	and percentage of pregnant		
	women with known status	m /-	
	(includes women who were	n/a	
	tested for HIV and received		
PMTCT_STAT_TA	their results) (TA)		
	Number of pregnant women		
	with known HIV status		
	(includes women who were		17,195
	tested for HIV and received		, 55
	their results)		
	in in roodito)		



Number of new ANC and	17,195
L&D clients	2.022
By: Known positives at ent	
By: Number of new positive identified	1,417
Sum of Positives Status disaggregates	4,450
Required only for DREAMS countries - By known positives: <15	8
Required only for DREAMS countries - By known positives: 15-19	5
Required only for DREAMS countries - By known positives: 20-24	5
Required only for DREAMS countries - By known positives: 25+	8
Required only for DREAMS countries - By new positive <15	
Required only for DREAMS countries - By new positive 15-19	
Required only for DREAMS countries - By new positive 20-24	
Required only for DREAMS countries - By new positive 25+	
Required only for DREAMS countries - Denominator: <	
Required only for DREAMS countries - Denominator:	8



	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	n/a	
DMTCT ABV DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		16
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		16
	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		11
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		5



	Maternal triple ARV		
	prophylaxis (provided with		
	the intention to stop at the		
	end of the breastfeeding		
	period)		
	Maternal AZT (prophylaxis		
	component of WHO Option A		
	during pregnancy and		
	delivery)		
	Single-dose nevirapine (with		
	or without tail)		
	Sum of Regimen Type		
	disaggregates		
	Sum of New and Current		16
	disaggregates		10
	PMTCT_ARV_TA		
	Percentage of HIV-positive		
	pregnant women who		
	received antiretrovirals to	n/a	
	reduce risk for	II/a	
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	and delivery (TA)		
	Number of HIV-positive		
DMTCT ADV TA	pregnant women who		
PMTCT_ARV_TA	received antiretrovirals to		
	reduce risk of		4,542
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	and delivery		
	Number of HIV- positive		
	pregnant women identified in		
	the reporting period		4,542
	(including known		
	HIV-positive at entry)		



	i i	ı	
	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART:		
	Newly initiated on treatment		2,719
	during the current pregnancy		2,
	Sub-Disag of Life-long ART:		
	Already on treatment at the		
	beginning of the current		1,810
	pregnancy		
	Maternal triple ARV		
	prophylaxis (provided with		
	the intention to stop at the		
	end of the breastfeeding		
	period)		
	Maternal AZT (prophylaxis		
	component of WHO Option A		
	during pregnancy and		
	delivery)		
	Single-dose nevirapine (with		
	or without tail)		
	Sum of Regimen Type		
	disaggregates		
	Sum of New and Current		
	disaggregates		4,529
	PMTCT_FO_TA Final		
	outcomes among HIV	,	
	exposed infants registered in	n/a	
	the birth cohort		
	Number of HIV-exposed		
PMTCT_FO_TA	infants with a documented		
	outcome by 18 months of		3,193
	age disaggregated by		
	outcome type.		
	Number of HIV-exposed		2 102
	infants registered in the birth		3,193



	<u> </u>	I
	cohort at any time between 0	
	and 18 months of age	
	(including transfer-ins)	
	HIV-infected: Linked to ART	
	HIV-infected: Not linked to	
	ART	
	HIV-infected: Unknown link	
	HIV-uninfected:	
	Breastfeeding status	
	unknown	
	HIV-uninfected: Not	
	breastfeeding	
	HIV-uninfected: Still	
	breastfeeding	
	Other: Died	
	Other: In care but no test	
	done	
	Other: Lost to follow-up	
	Other: Transferred out	
	Number of males	
	circumcised surgically or by	
	medical device that	292
	experienced at least one	292
	moderate or severe adverse	
	event(s) (AEs)	
	By AE type: Number of	
VMMC_AE_DSD	VMMC clients with one or	
	more moderate or severe	
	surgical intra-operative AE(s)	
	Sub-Disag: Surgical	
	intra-operative AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more moderate surgical	
	intra-operative AE(s), but no	



T	
severe surgical	
intra-operative AE(s)	
Sub-Disag: Surgical	
intra-operative AE(s) by	
maximum severity category:	
Number of clients with one or	
more severe surgical	
intra-operative AE(s)	
By AE Type: Number of	
VMMC clients with one or	
more moderate or severe	
surgical post-operative AE(s)	
Sub-Disag: By Surgical	
post-operative AE(s) by	
maximum severity category:	
Number of clients with one or	
more moderate surgical	
post-operative AE(s), but no	
severe surgical	
post-operative AE(s)	
Sub-Disag: By Surgical	
post-operative AE(s) by	
maximum severity category:	
Number of clients with one or	
more severe surgical	
intra-operative AE(s)	
By AE Type: Number of VMMC clients with one or	
more moderate or severe	
medical device-related AE(s)	
Sub-Disag: By Medical	
device-based AE(s) by	
maximum severity category:	
Number of clients with one or	
more moderate medical	
device-related AE(s), but no	



	severe medical	
	device-related AE(s)	
	Sub-Disag: By Medical	
	device-based AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more severe medical	
	device-related AE(s)	
	Number of males	
	circumcised surgically or by	
	medical device that	
	experienced at least one	38
	moderate or severe adverse	
	event(s) (AEs)	
	By AE Type: Number of	
	VMMC clients with one or	
	more moderate or severe	
	medical device-related AE(s)	
	By AE Type: Number of VMMC clients with one or	
	more moderate or severe	
VMMC_AE_TA	surgical post-operative AE(s)	
	By AE type: Number of	
	VMMC clients with one or	
	more moderate or severe	
	surgical intra-operative AE(s)	
	Sub-Disag: By Medical	
	device-based AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more moderate medical	
	device-related AE(s), but no	
	severe medical	
	device-related AE(s)	
	Sub-Disag: By Medical	
	device-based AE(s) by	
	· · · · · · · · · · · · · · · · · · ·	



	1	
	maximum severity category:	
	Number of clients with one or	
	more severe medical	
	device-related AE(s)	
	Sub-Disag: By Surgical	
	post-operative AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more severe surgical	
	intra-operative AE(s)	
	Sub-Disag: By Surgical	
	post-operative AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more moderate surgical	
	post-operative AE(s), but no	
	severe surgical	
	post-operative AE(s)	
	Sub-Disag: Surgical	
	intra-operative AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more moderate surgical	
	intra-operative AE(s), but no	
	severe surgical	
	intra-operative AE(s)	
	Sub-Disag: Surgical	
	intra-operative AE(s) by	
	maximum severity category:	
	Number of clients with one or	
	more severe surgical	
	intra-operative AE(s)	
	Number of males	
	circumcised as part of the	
VMMC_CIRC_DSD	voluntary medical male	14,600
	circumcision (VMMC) for HIV	



	prevention program within the reporting period	
İ	By Age: <1	0
j	By Age: 1-9	0
	By Age: 10-14	0
	By Age: 15-19	10,074
i	By Age: 20-24	2,628
	By Age: 25-29	1,898
	By Age: 30-49	0
Ĭ	By Age: 50+	0
	Sum of age disaggregates	12,702
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	37
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	693
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	13,870
	By circumcision technique: Surgical VMMC	14,375
	By circumcision technique: Device-based VMMC	225
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,937
	By follow-up status: Number	1,438



	of surgically circumcised	
	clients who did NOT return	
	for follow-up care within 14	
	days of circumcision surgery	
	Number of males	
	circumcised as part of the	
	voluntary medical male	2,600
	circumcision (VMMC) for HIV	2,000
	prevention program within	
	the reporting period	
	By Age: <1	1,200
	By Age: 1-9	0
	By Age: 10-14	70
	By Age: 15-19	252
	By Age: 20-24	420
	By Age: 25-29	420
	By Age: 30-49	210
	By Age: 50+	28
VMMC_CIRC_TA	Sum of Age disaggregations	1,970
	By HIV status: Number of	
	HIV-positive clients (tested	56
	HIV positive at VMMC site)	
	By HIV status: Number of	
	HIV-negative clients (tested	4 000
	HIV negative at VMMC	1,330
	program	
	By HIV status: Number of	
	clients with	
	undocumented/indeterminate	1,214
	HIV status or not tested for	
	HIV at site	
	By circumcision technique:	1 400
	Surgical VMMC	1,400
	By circumcision technique:	1,200



	Device-based VMMC		
	By follow-up status: Number		
	of surgically circumcised		
	clients who returned at least		
	once for follow-up care within		1,120
	14 days of circumcision		
	surgery		
	By follow-up status: Number		
	of surgically circumcised		
	clients who did NOT return		280
	for follow-up care within 14		
	days of circumcision surgery		
	PP_PREV_DSD Percentage		
	of the target population who		
	completed a standardized		
	HIV prevention intervention	n/a	
	including the minimum		
	components during the		
	reporting period (DSD)		
	Number of the target		
	population who completed a		
	standardized HIV prevention		20,000
	intervention including the		20,000
DD DDEW DOD	minimum components during		
PP_PREV_DSD	the reporting period.		
	Total number of people in the		02.602
	target population		92,603
	Age/sex: 10-14 Male		285
	Age/sex: 15-19 Male		1,555
	Age/sex: 20-24 Male		2,010
	Age/sex: 25-49 Male		1,160
	Age/sex: 50+ Male		475
	Age/sex: 10-14 Female		340
	Age/sex: 15-19 Female		6,236
	Age/sex: 20-24 Female	_	4,804



	Age/sex: 25-49 Female		2,485
	Age/sex: 50+ Female		650
	Sum of Age/Sex		20,000
	disaggregates		20,000
	PP_PREV_TA Percentage of		
	the target population who		
	completed a standardized		
	HIV prevention intervention	n/a	
	including the minimum		
	components during the		
	reporting period (TA-only)		
1	Number of the target		
	population who completed a		
	standardized HIV prevention		13,620
	intervention including the		·
	minimum components during		
	the reporting period.		
PP_PREV_TA	Total number of people in the		1,266,334
11_1 NEV_1A	target population		. ,
	Age/sex: 10-14 Male		3,407
	Age/sex: 15-19 Male		2,041
	Age/sex: 20-24 Male		272
	Age/sex: 25-49 Male		954
	Age/sex: 50+ Male		0
	Age/sex: 10-14 Female		3,541
	Age/sex: 15-19 Female		2,179
	Age/sex: 20-24 Female		272
	Age/sex: 25-49 Female		954
	Age/sex: 50+ Female		0
	Sum of Age/Sex		40.000
	disaggregates		13,620
	KP_PREV_DSD Percentage		
KP_PREV_DSD	of key populations reached	n/a	
	with individual and/or small		



	r	
group level HIV preventive		
interventions that are based		
on evidence and/or meet the		
minimum standards required		
(DSD)		
Number of key populations		
reached with individual		
and/or small group level HIV		
preventive interventions that		5,364
are based on evidence		
and/or meet the minimum		
standards required		
Total estimated number of		
key population in the		5,763
catchment area		,
By key population type:		
Female sex workers (FSW)		
(Numerator: Number of key		
populations reached with		
individual and/or small group		4,515
level HIV preventive		.,010
interventions that are based		
on evidence and/or meet the		
minimum standards required)		
By key population type:		
Males who inject drugs (
Male PWID) (Numerator:		
Number of key populations reached with individual		
		0
and/or small group level HIV		
preventive interventions that		
are based on evidence		
and/or meet the minimum		
standards required)		
By key population type:		0
Females who inject drugs		



(Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based
reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
are based on evidence and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
and/or meet the minimum standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
standards required) By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive
(Numerator: Number of key populations reached with individual and/or small group level HIV preventive
populations reached with individual and/or small group level HIV preventive
individual and/or small group level HIV preventive
level HIV preventive
interventions that are pased
on evidence and/or meet the
minimum standards required)
By key population type:
MSM/TG who are male sex
workers (subset MSM/TG)
(Numerator: Number of key
populations reached with
individual and/or small group
level HIV preventive
interventions that are based
on evidence and/or meet the
minimum standards required)
By key population type:
Female sex workers (FSW)
(Denominator: Total 4,7
estimated number of key
population in the catchment
area)
By key population type:
Males who inject drugs (



	Male PWID) (Denominator:	
	Total estimated number of	
	key population in the	
	catchment area)	
	By key population type:	
	Females who inject drugs	
	(Female PWID)	
	(Denominator: Total	
	estimated number of key	
	population in the catchment	
	area)	
	By key population type: Men	
	who have sex with	
	men/Transgender (MSM/TG)	
	(Denominator: Total	
	estimated number of key	
	population in the catchment	
	area)	
	By key population type:	
	MSM/TG who are male sex	
	workers (subset MSM/TG)	
	(Denominator: Total	
	estimated number of key	
	population in the catchment	
	area)	
	Number of individuals who	
	received T&C services for	
	HIV and received their test	135,019
	results during the past 12	,,,,,,
	months	
HTC_TST_DSD	By Test Result: Negative	116,222
	By Test Result: Positive	18,797
	Sum of Test Result	, -
	disaggregates	135,019
	Test Result by Age and Sex:	0
	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	



Positive: <1 Male	
Test Result by Age and Sex:	47
Positive: 1-4 Male	
Test Result by Age and Sex:	88
Positive: 5-9 Male	33
Test Result by Age and Sex:	253
Positive: 10-14 Male	255
Test Result by Age and Sex:	498
Positive: 15-19 Male	455
Test Result by Age and Sex:	1,986
Positive: 20-24 Male	1,500
Test Result by Age and Sex:	4,695
Positive: 25-49 Male	4,000
Test Result by Age and Sex:	795
Positive: 50+ Male	733
Test Result by Age and Sex:	0
Positive: <1 Female	0
Test Result by Age and Sex:	55
Positive: 1-4 Female	33
Test Result by Age and Sex:	104
Positive: 5-9 Female	104
Test Result by Age and Sex:	300
Positive: 10-14 Female	300
Test Result by Age and Sex:	633
Positive: 15-19 Female	033
Test Result by Age and Sex:	2,529
Positive: 20-24 Female	2,329
Test Result by Age and Sex:	5 907
Positive: 25-49 Female	5,897
Test Result by Age and Sex:	013
Positive: 50+ Female	912
Test Result by Age and Sex:	
Negative: <1 Male	0
Test Result by Age and Sex:	389



Negative: 1-4 Male	
Test Result by Age and S Negative: 5-9 Male	Sex: 695
Test Result by Age and S Negative: 10-14 Male	Sex: 1,754
Test Result by Age and S Negative: 15-19 Male	Sex: 3,286
Test Result by Age and S Negative: 20-24 Male	Sex: 12,913
Test Result by Age and S Negative: 25-49 Male	Sex: 30,503
Test Result by Age and S Negative: 50+ Male	Sex: 5,362
Test Result by Age and S Negative: <1 Female	Sex: 0
Test Result by Age and S Negative: 1-4 Female	Sex: 409
Test Result by Age and S Negative: 5-9 Female	Sex: 735
Test Result by Age and S Negative: 10-14 Female	Sex: 1,896
Test Result by Age and S Negative: 15-19 Female	Sex: 3,670
Test Result by Age and S Negative: 20-24 Female	Sex: 14,521
Test Result by Age and S Negative: 25-49 Female	Sex: 34,237
Test Result by Age and S Negative: 50+ Female	Sex: 5,857
Aggregated Age/sex - US WITH HQ PERMISSION ONLY: <15 Male	SE 3,224
Aggregated Age/sex - US WITH HQ PERMISSION	SE 60,039



ONLY: 15+ Male Aggregated Age/sex - USE WITH HQ PERMISSION 3,49 ONLY: <15 Female Aggregated Age/sex - USE	-
WITH HQ PERMISSION 3,49 ONLY: <15 Female	
ONLY: <15 Female	
	19
Aggregated Agg/gay - USE	_
Aggregated Age/Sex - USE	
WITH HQ PERMISSION 68,25	57
ONLY: 15+ Female	
Sum of Aggregated Age/Sex 6,72	23
<15	
Sum of Aggregated Age/Sex	36
15+	
Sum of Aggregated Age/Sex 135,01	a
disaggregates	_
Service Delivery Point by	
Result: Antenatal Clinic - All	
results	
Service Delivery Point by	
Result: Antenatal Clinic -	
Positive	_
Service Delivery Point by	
Result: Antenatal Clinic -	
Negative	
Service Delivery Point by	
Result: Labor & delivery - All	
results	_
Service Delivery Point by	
Result: Labor & delivery -	
Positive	
Service Delivery Point by	
Result: Labor & delivery -	
Negative	
Service Delivery Point by	
Result: Under 5 Clinic – All	
results	_
Service Delivery Point by	



I	ı	
Result: Under 5 Clinic - Positive		
Service Delivery Point by Result: Under 5 Clinic -		
Negative		
Service Delivery Point by		
Result: Maternal and Child		
Health Clinic – All Results		
Service Delivery Point by		
Result: Maternal and Child		
Health Clinic - Positive		
Service Delivery Point by		
Result: Maternal and Child		
Health Clinic - Negative		
Service Delivery Point by		
Result: Tuberculosis – All		
results		
Service Delivery Point by		
Result: Tuberculosis -		
Positive		
Service Delivery Point by		
Result: Tuberculosis -		
Negative		
Service Delivery Point by		
Result: Sexually Transmitted		
Infections – All Results		
Service Delivery Point by		
Result: Sexually Transmitted		
Infections - Positive		
Service Delivery Point by		
Result: Sexually Transmitted		
Infections - Negative		
Service Delivery Point by		
Result: Outpatient		
Department – All Results		



Service Delivery Point by	
Result: Outpatient	
Department - Positive	
Service Delivery Point by	
Result: Outpatient	
Department - Negative	
Service Delivery Point by	
Result: Inpatient – All	
Results	
Service Delivery Point by	
Result: Inpatient - Positive	
Service Delivery Point by	
Result: Inpatient - Negative	
Service Delivery Point by	
Result: HIV care and	
treatment clinic – All Results	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Positive	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Negative	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision – All	
Results	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Positive	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) – All	



Results	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) - All	
Results	
Service Delivery Point by	
Result: Voluntary Counseling	E 740
& Testing (stand alone) –	5,749
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	20 500
& Testing (stand alone) -	36,529
Negative	
Service Delivery Point by	20.711
Result: Mobile – All Results	92,741
Service Delivery Point by	
Result: Mobile - Positive	13,049
Service Delivery Point by	
Result: Mobile - Negative	79,692
Service Delivery Point by	
Result: Home-based – All	
Results	
Service Delivery Point by	
Result: Home-based -	
Positive	
Service Delivery Point by	
 Result: Home-based -	



	Negative	
	Service Delivery Point by	
	Result: Other – All Results	
	Service Delivery Point by	
	Result: Other - Positive	
	Service Delivery Point by	
	Result: Other - Negative	
	Number of individuals who	
	received T&C services for	
	HIV and received their test	225,903
	results during the past 12	
	months	
	By Test Result: Negative	196,509
	By Test Result: Positive	29,394
	Sum of Test Result	
	disaggregates	225,903
	Test Result by Age and Sex:	0.50
	Positive: <1 Male	353
	Test Result by Age and Sex:	4.407
	Positive: 1-4 Male	1,127
HTC_TST_TA	Test Result by Age and Sex:	4 000
	Positive: 5-9 Male	1,329
	Test Result by Age and Sex:	4 000
	Positive: 10-14 Male	1,296
	Test Result by Age and Sex:	4 400
	Positive: 15-19 Male	1,422
	Test Result by Age and Sex:	
	Positive: 20-24 Male	1,652
	Test Result by Age and Sex:	
	Positive: 25-49 Male	
	Test Result by Age and Sex:	
	Positive: 50+ Male	1,580
	Test Result by Age and Sex:	
	Positive: <1 Female	345



1,115	Test Result by Age and Sex: Positive: 1-4 Female
1,312	Test Result by Age and Sex: Positive: 5-9 Female
1,282	est Result by Age and Sex: ositive: 10-14 Female
1,499	est Result by Age and Sex: Positive: 15-19 Female
1,838	Test Result by Age and Sex: Positive: 20-24 Female
5,805	est Result by Age and Sex: Positive: 25-49 Female
1,913	rest Result by Age and Sex: Positive: 50+ Female
2,329	Test Result by Age and Sex: Negative: <1 Male
7,482	Test Result by Age and Sex: Negative: 1-4 Male
8,804	Test Result by Age and Sex: Negative: 5-9 Male
8,598	est Result by Age and Sex:
9,517	est Result by Age and Sex: legative: 15-19 Male
11,573	Test Result by Age and Sex: Negative: 20-24 Male
38,059	est Result by Age and Sex: legative: 25-49 Male
10,379	Fest Result by Age and Sex: Negative: 50+ Male
2,274	Fest Result by Age and Sex: Negative: <1 Female
7,380	est Result by Age and Sex: legative: 1-4 Female



Test Result by Age and Sex: Negative: 5-9 Female	8,703
Test Result by Age and Sex: Negative: 10-14 Female	8,471
Test Result by Age and Sex: Negative: 15-19 Female	9,977
Test Result by Age and Sex: Negative: 20-24 Female	11,765
Test Result by Age and Sex: Negative: 25-49 Female	38,474
Test Result by Age and Sex: Negative: 50+ Female	12,724
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	31,318
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	79,697
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	30,884
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	84,004
Sum of Aggregated Age/Sex <15	62,202
Sum of Aggregated Age/Sex 15+	163,701
Sum of Aggregated Age/Sex disaggregates	225,903
Service Delivery Point by Result: Antenatal Clinic - All results	
Service Delivery Point by	



Result: Antenatal Clinic -	
Positive	
Service Delivery Point by	
Result: Antenatal Clinic -	
Negative	
Service Delivery Point by	
Result: Labor & delivery - All	
results	
Service Delivery Point by	
Result: Labor & delivery -	
Positive	
Service Delivery Point by	
Result: Labor & delivery -	
Negative	
Service Delivery Point by	
Result: Under 5 Clinic – All	
results	
Service Delivery Point by	
Result: Under 5 Clinic -	
Positive	
Service Delivery Point by	
Result: Under 5 Clinic -	
Negative	
Service Delivery Point by	
Result: Maternal and Child	14,182
Health Clinic – All Results	·
Service Delivery Point by	
Result: Maternal and Child	1,417
Health Clinic - Positive	,
Service Delivery Point by	
Result: Maternal and Child	12,765
Health Clinic - Negative	12,130
Service Delivery Point by	
Result: Tuberculosis – All	2,181
results	۷,۱۵۱
เธอนแอ	



Service Delivery Point by Result: Tuberculosis - Positive	1,054
Service Delivery Point by Result: Tuberculosis - Negative	1,127
Service Delivery Point by Result: Sexually Transmitted Infections – All Results	
Service Delivery Point by Result: Sexually Transmitted Infections - Positive	
Service Delivery Point by Result: Sexually Transmitted Infections - Negative	
Service Delivery Point by Result: Outpatient Department – All Results	
Service Delivery Point by Result: Outpatient Department - Positive	
Service Delivery Point by Result: Outpatient Department - Negative	
Service Delivery Point by Result: Inpatient – All Results	
Service Delivery Point by Result: Inpatient - Positive	
Service Delivery Point by Result: Inpatient - Negative	
Service Delivery Point by Result: HIV care and treatment clinic – All Results	203,540
Service Delivery Point by	26,321



1	
	Result: HIV care and
	treatment clinic - Positive
	Service Delivery Point by
177,219	Result: HIV care and
	treatment clinic - Negative
	Service Delivery Point by
	Result: Voluntary Medical
	Male Circumcision – All
	Results
	Service Delivery Point by
	Result: Voluntary Medical
	 Male Circumcision - Positive
	Service Delivery Point by
	Result: Voluntary Medical
	Male Circumcision - Negative
	Service Delivery Point by
	Result: Voluntary Counseling
	& Testing (co-located) – All
	Results
	Service Delivery Point by
600	Result: Voluntary Counseling
600	& Testing (co-located) -
	Positive
	Service Delivery Point by
5.400	Result: Voluntary Counseling
5,400	& Testing (co-located) -
	Negative
	 Service Delivery Point by
	Result: Voluntary Counseling
	 & Testing (standalone) - All
	Service Delivery Point by
	Result: Voluntary Counseling
	R Testing (standalone) -
i	= :
	Positive



Result: Voluntary Counseling & Testing (standalone) - Negative	
Service Delivery Point by Result: Mobile – All Results	
Service Delivery Point by Result: Mobile - Positive	
Service Delivery Point by Result: Mobile - Negative	
Service Delivery Point by Result: Home-based – All Results	
Service Delivery Point by Result: Home-based - Positive	
Service Delivery Point by Result: Home-based - Negative	
Service Delivery Point by Result: Other – All Results	
Service Delivery Point by Result: Other - Positive	
Service Delivery Point by Result: Other - Negative	
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+	



	Female		
	Test Result by Aggregated		
	Age and Sex: Positive <15 Male		
	Test Result by Aggregated Age and Sex: Positive 15+ Male		
	Test Result by Aggregated Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		
	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		2,891
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.		3,520
	Age 15-19		
	Age: <1		69
	Age: 1-4		199
	Age: 10-14		217
	Age: 20+		1,925
	Age: 5-9		209
	Sex: Female		1,227
	Sex: Male		1,664
	Status: Negative		1,128



	Status: Positive	1,763
	Number of people receiving post-GBV care	4,323
	Age/Sex: <10 Male	40
	Age/Sex: 10-14 Male	96
	Age/Sex: 15-17 Male	210
	Age/Sex: 18-24 Male	315
	Age/Sex: 25+ Male	540
	Age/Sex: <10 Female	60
	Age/Sex: 10-14 Female	295
	Age/Sex: 15-17 Female	469
GEND_GBV_DSD	Age/Sex: 18-24 Female	844
02110_001_000	Age/Sex: 25+ Female	1,454
	Sum of Age/Sex Disaggregates	4,323
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,423
	By type of service: Sexual Violence (Post-Rape Care)	1,324
	By PEP service provision (related to sexual violence services provided)	
	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	15,238
	Age/Sex: <10 Male	55
GEND_NORM_DSD	Age/Sex: 10-14 Male	663
	Age/Sex: 15-19 Male	1,341
	Age/Sex: 20-24 Male	1,684
	Age/Sex: 25+ Male	1,195
	Age/Sex: <10 Female	180



	Age/Sex: 10-14 Female	963
	Age/Sex: 15-19 Female	3,583
	Age/Sex: 20-24 Female	3,643
	Age/Sex: 25+ Female	1,931
	By Age: 0-9	
	By Age: 10-14	
	By Age: 15-19	
	By Age: 20-24	
	By Age: 25+	
	Sum of Age disaggregates	
	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	6,670
	Age/Sex: <1 Male	24
	Age/Sex: 1-4 Male	503
	Age/Sex: 5-9 Male	450
	Age/Sex: 10-14 Male	416
	Age/Sex: 15-17 Male	195
	Age/Sex: 18-24 Male	208
OVC_ACC_DSD	Age/Sex: 25+ Male	505
	Age/Sex: <1 Female	22
	Age/Sex: 1-4 Female	498
	Age/Sex: 5-9 Female	453
	Age/Sex: 10-14 Female	431
	Age/Sex: 15-17 Female	187
	Age/Sex: 18+ Female	
	Age/Sex: 18-24 Female	463
	Age/Sex: 25+ Female	2,315
	Sum of Age/Sex disaggregates	6,670



	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,119
	Age/Sex: <1 Male	43
	Age/Sex: 1-4 Male	843
	Age/Sex: 5-9 Male	754
	Age/Sex: 10-14 Male	692
	Age/Sex: 15-17 Male	327
	By: Age/sex: Male 18-24	356
	By: Age/sex: Male 25+	881
	Age/Sex: <1 Female	37
	Age/Sex: 1-4 Female	828
	Age/Sex: 5-9 Female	755
	Age/Sex: 10-14 Female	713
OVC_SERV_DSD	Age/Sex: 15-17 Female	312
	By: Age/sex: 18-24 Female	765
	By: Age/sex: 25+ Female	3,813
	Sum of Age/Sex disaggregates	5,304
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9	
	Required only for DREAMS	



<u></u>	
countries - By service, age	
and sex: Education Support	
Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Male 15-17	
IVIAIS 13-11	



1	1	
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
. 5 5 -	ı	



Programs Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Female <1	
Required only for DREAMS	
countries - By service, age	



Ţ.	,	
and sex: Social Protection Female 1-4		
Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
Required only for DREAMS		



countries - By service, age	
and sex: Social Protection	
Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Male 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Social Protection	
Male 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female <1	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 15-17	



1	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
Strengthening Male 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Economic	
COM 20011011110	



	Strengthening Male 25+	
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,500
	Age/Sex: <1 Male	0
	Age/Sex: 1-4 Male	86
	Age/Sex: 5-9 Male	97
	Age/Sex: 10-14 Male	141
	Age/Sex: 15-17 Male	157
	By age/sex: 18-24 Male	136
	By age/sex: 25+ Male	3
	Age/Sex: <1 Female	0
	Age/Sex: 1-4 Female	76
	Age/Sex: 5-9 Female	86
	Age/Sex: 10-14 Female	271
OVC_SERV_TA	Age/Sex: 15-17 Female	271
	By age/sex: 18-24 Female	142
	By age/sex: 25+ Female	34
	Sum of Age/Sex disaggregates	1,088
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	



1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	



Support Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Education	
Support Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex:	
Parenting/Caregiver Program	
Female 10-14	
Required only for DREAMS	
countries: By Service Area, age and sex:	
Parenting/Caregiver Program	
Female 15-17	
Required only for DREAMS	



	1
countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24 Required only for DREAMS countries: By Service Area, age and sex:	
Parenting/Caregiver Program Female 25+	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
Required only for DREAMS countries: By Service Area,	



age and sex:
Parenting/Caregiver Program
Male 18-24
Required only for DREAMS
countries: By Service Area,
age and sex:
Parenting/Caregiver Program
Male 25+
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female <1
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female 1-4
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female 5-9
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female 10-14
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female 15-17
Required only for DREAMS
countries: By Service Area,
age and sex: Social
Protection Female 18-24
Required only for DREAMS
countries: By Service Area,
age and sex: Social



ı	
Protection Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Social	
Protection Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female <1	
Required only for DREAMS	
countries: By Service Area,	
countiles. By Service Area,	



age and sex: Economic	
Strengthening Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Female 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 5-9	
Required only for DREAMS	
 IVEdailed Olliv IOI DKEAIVIS	



countries: By Service Area,	
age and sex: Economic	
Strengthening Male 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 15-17	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 18-24	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Economic	
Strengthening Male 25+	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female <1	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female 1-4	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female 5-9	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female 10-14	
Required only for DREAMS	
countries: By Service Area,	
age and sex: Other Service	
Areas Female 15-17	



	Required only for DREAMS	
	countries: By Service Area,	
	age and sex: Other Service	
	Areas Female 18-24	
	Required only for DREAMS	
	countries: By Service Area,	
	age and sex: Other Service	
	Areas Female 25+	
	Number of HIV positive	
	adults and children who	
	received at least one of the	
	following during the reporting	1,862
	period: clinical assessment	
	(WHO staging) OR CD4	
	count OR viral load	
	Age/sex: <1 Male	0
	Age/sex: 1-4 Male	0
	Age/sex: 5-9 Male	12
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	0
	Age/sex: 20-24 Male	0
CARE_CURR_DSD	Age/sex: 25-49 Male	224
	Age/sex: 50+ Male	12
	Age/sex: <1 Female	0
	Age/sex: 1-4 Female	0
	Age/sex: 5-9 Female	0
	Age/sex: 10-14 Female	6
	Age/sex: 15-19 Female	157
	Age/sex: 20-24 Female	621
	Age/sex: 25-49 Female	679
	Age/sex: 50+ Female	151
	Sun of Age/Sex	
	disaggregates	1,862
	Aggregated Age/sex - USE	
	1 55 5 5	ı



Γ		
	WITH HQ PERMISSION	
	ONLY: <15 Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: 15+ Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: <15 Female	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: 15+ Female	
	Sum of Aggregated Age/Sex	
	disaggregates	
	Number of HIV positive	
	adults and children who	
	received at least one of the	
	following during the reporting	105,107
	period: clinical assessment	
	(WHO staging) OR CD4 count OR viral load	
		1 004
	Age/sex: <1 Male	1,004
	Age/sex: 1-4 Male	3,087
	Age/sex: 5-9 Male	3,642
CARE_CURR_TA	Age/sex: 10-14 Male	3,498
	Age/sex: 15-19 Male	4,710
	Age/sex: 20-24 Male	7,454
	Age/sex: 25-49 Male	24,076
	Age/sex: 50+ Male	4,059
	Age/sex: <1 Female	1,012
	Age/sex: 1-4 Female	3,040
	Age/sex: 5-9 Female	3,646
	Age/sex: 10-14 Female	3,598
	Age/sex: 15-19 Female	5,412
	Age/sex: 20-24 Female	8,012
	rigoroom Lo L i i omalo	5,012



	Age/sex: 25-49 Female	24,472
	Age/sex: 50+ Female	4,385
	Sum of Age/Sex	405 407
	disaggregates	105,107
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: <15 Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: 15+ Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: <15 Female	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	
	ONLY: 15+ Female	
	Sum of Aggregated Age/Sex	
	disaggregates	
	Number of HIV-infected	
	adults and children newly	
	enrolled in clinical care	
	during the reporting period	
	and received at least one of	1,109
	the following at enrollment:	
	clinical assessment (WHO	
	staging) OR CD4 count OR	
CARE_NEW_DSD	viral load	
	Age/sex: <1 Male	3
	Age/sex: 1-4 Male	0
	Age/sex: 5-9 Male	2
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	0
	Age/sex: 20-24 Male	0
	Age/sex: 25-49 Male	44



	Age/sex: 50+ Male	2
	Age/sex: <1 Female	0
	Age/sex: 1-4 Female	0
	Age/sex: 5-9 Female	0
	Age/sex: 10-14 Female	1
	Age/sex: 15-19 Female	104
	Age/sex: 20-24 Female	418
	Age/sex: 25-49 Female	432
	Age/sex: 50+ Female	103
	Sum of Age/sex disaggregates	1,109
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
	Sum of Aggregated Age/sex disaggregates	
	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment:	43,492
CARE_NEW_TA	clinical assessment (WHO staging) OR CD4 count OR viral load	
	Age/sex: <1 Female	522
	Age/sex: 1-4 Female	1,685
	Age/sex: 5-9 Female	1,991
	Age/sex: 10-14 Female	1,929



	Age/sex: 15-19 Female		2,249
	Age/sex: 20-24 Female		2,604
	Age/sex: 25-49 Female		8,482
	Age/sex: 50+ Female		2,827
	Age/sex: <1 Male		530
	Age/sex: 1-4 Male		1,709
	Age/sex: 5-9 Male		2,015
	Age/sex: 10-14 Male		1,955
	Age/sex: 15-19 Male		2,131
	Age/sex: 20-24 Male		2,438
	Age/sex: 25-49 Male		8,140
	Age/sex: 50+ Male		2,285
	Aggregated Age/sex: <15 Female		,
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Female		
	Aggregated Age/sex: 15+ Male		
	Sum of Aggregated Age/sex disaggregates		
	Sum of age/sex disaggregates		43,492
	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
TB_ART_TA	The number of registered new and relapse TB cases with documented		
	HIV-positive status who are on ART during TB treatment		1,763
	during the reporting period		



	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		1,763
	Age: <1		41
	Age: 1-4		119
	Age: 5-9		126
	Age: 10-14		130
	Age: 15-19		170
	Age: 20+		1,177
	Sum of Age disaggregates		1,763
	Aggregated Age: <15		425
	Aggregated Age: 15+		1,338
	Sum of Aggregated Age disaggregates		1,763
	Male		864
	Female		899
	Sum of Sex disaggregates		1,763
	Known HIV-positive		704
	Newly tested		
	Sum of Test Status disaggregates		704
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical	n/a	



	visit to an HIV care facility		
	during the reporting period.		
	The number of PLHIV who		
	were screened for TB		
	symptoms at the last clinical		105,107
	visit to an HIV care facility		
	during the reporting period		
	Number of HIV positive		
	adults and children who		
	received at least one of the		
	following during the reporting		105,107
	period: clinical assessment		
	(WHO staging) OR CD4		
	count OR viral load		
	Age: <1		2,005
	Age: 1-4		6,127
	Age: 5-9		7,291
	Age: 10-14		7,105
	Age: 15-19		10,124
	Age: 20+		72,455
	Sum of Age disaggregates		105,107
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		
	<15		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		
	15+		
	Sum of Aggregated Age		
	disaggregates		
	Sex: Female		53,573
	Sex: Male		51,534
	Sum of Sex disaggregates		105,107
PMTCT_EID_TA	PMTCT_EID_TA Percent of	n/a	
LIMITOI EID I H	infants born to HIV-positive	II/a	



	1		
	women that receive a		
	virological HIV test within 12		
	months of birth (TA)		
	Number of infants who had a		
	virologic HIV test within 12		2 002
	months of birth during the		3,992
	reporting period		
	Number of HIV- positive		
	pregnant women identified		
	during the reporting period		
	(include known HIV-positive		
	women at entry into PMTCT)		
	By infants who received a		
	virologic test within 2 months		
	of birth		
	By infants who received their		
	first virologic HIV test		
	between 2 and 12 months of		
	age		
	Sum of Infant Age		
	disaggregates		
	By infants with a positive		
	virologic test result within 12		
	months of birth		
	Number of infants with a		
	positive virological test result		
	within 2 months of birth		
	Number of infants with a		
	positive virological test result		
	within 12 months of birth		
	PMTCT_CTX_TA		
	Percentage of infants born to		
PMTCT CTX TA		n/a	
	women who were started on		
PMTCT_CTX_TA	HIV-positive pregnant	n/a	



	prophylaxis within two	
	months of birth	
	Number of infants born to HIV-infected women who were started on cotrimoxizole	
	(CTX) prophylaxis within two	3,992
	reporting period	
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)	
	Number of HIV-infected adults and children receiving	35,003
	care and support services outside of the health facilitY	
	Age/Sex: <1 Male	166
	Age/Sex: 1-4 Male	397
	Age/Sex: 5-9 Male	598
	Age/Sex: 10-14 Male	875
	Age/Sex: 15-19 Male	688
	Age/Sex: 20-24 Male	516
CARE_COMM_DSD	Age/Sex: 25-49 Male	8,254
	Age/Sex: 50+ Male	1,911
	Age/Sex: <1 Female	161
	Age/Sex: 1-4 Female	473
	Age/Sex: 5-9 Female	710
	Age/Sex: 10-14 Female	791
	Age/Sex: 15-19 Female	912
	Age/Sex: 20-24 Female	1,655
	Age/Sex: 25-49 Female	14,041
	Age/Sex: 50+ Female	2,855
CARE_COMM_TA	Number of HIV-infected adults and children receiving	1,000



	care and support services	
	outside of the health facilitY	
	Age/Sex: <1 Female	0
	Age/Sex: <1 Male	0
	Age/Sex: 1-4 Female	0
	Age/Sex: 1-4 Male	0
	Age/Sex: 10-14 Female	87
	Age/Sex: 10-14 Male	65
	Age/Sex: 15-19 Female	87
	Age/Sex: 15-19 Male	67
	Age/Sex: 20-24 Female	72
	Age/Sex: 20-24 Male	62
	Age/Sex: 25-49 Female	382
	Age/Sex: 25-49 Male	178
	Age/Sex: 5-9 Female	0
	Age/Sex: 5-9 Male	0
	Age/Sex: 50+ Female	0
	Age/Sex: 50+ Male	0
	Number of adults and	9
	children receiving	2,392
	antiretroviral therapy (ART)	·
	Age/Sex: <1 Male	0
	Age/Sex: 1-4 Male	1
	Age/Sex: 5-14 Male	6
	Age/Sex: 15-19 Male	7
TX_CURR_DSD	Age/Sex: 20+ Male	200
	Age/Sex: <1 Female	0
	Age/Sex: 1-4 Female	0
	Age/Sex: 5-14 Female	8
	Age/Sex: 15-19 Female	216
	Age/Sex: 20+ Female	1,954
	Aggregated Age/Sex: <1	



	Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: 15+ Male	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex disaggregates	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Number of adults and children receiving antiretroviral therapy (ART)	144,664
	Age/Sex: <1 Male	1,745
	Age/Sex: 1-4 Male	5,760
	Age/Sex: 5-14 Male	13,344
	Age/Sex: 15-19 Male	7,220
TX_CURR_TA	Age/Sex: 20+ Male	42,407
	Age/Sex: <1 Female	1,756
	Age/Sex: 1-4 Female	5,648
	Age/Sex: 5-14 Female	13,258
	Age/Sex: 15-19 Female	7,554
	Age/Sex: 20+ Female	45,972
	Sum of Age/Sex	144,664



	disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	
	Sum of Aggregated Age/Sex disaggregates	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,345
	By Age/Sex: <1 Male	0
	By Age/Sex: 1-4 Male	0
TX_NEW_DSD	By Age/Sex: 5-9 Male	2
	By Age/Sex: 10-14 Male	0
	By Age/Sex: 15-19 Male	0
	By Age/Sex: 20-24 Male	0
	By Age/Sex: 25-49 Male	38
	By Age/Sex: 50+ Male	2
	By Age/Sex: <1 Female	0



	By Age/Sex: 1-4 Female	0
	By Age/Sex: 5-9 Female	0
	By Age/Sex: 10-14 Female	1
	By Age/Sex: 15-19 Female	130
	By Age/Sex: 20-24 Female	517
	By Age/Sex: 25-49 Female	527
	By Age/Sex: 50+ Female	128
	Sum of Age/Sex disaggregates	1,345
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	
	Sum of Aggregated Age/Sex disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Number of adults and children newly enrolled on	31,207
	antiretroviral therapy (ART)	070
TX_NEW_TA	By Age/Sex: <1 Male	373
	By Age/Sex: 1-4 Male	1,226
	By Age/Sex: 5-9 Male	1,447
	By Age/Sex: 10-14 Male	1,404
	By Age/Sex: 15-19 Male	1,530



	By Age/Sex: 20-24 Male		1,747
	By Age/Sex: 25-49 Male		5,830
	By Age/Sex: 50+ Male		1,642
	By Age/Sex: <1 Female		374
	By Age/Sex: 1-4 Female		1,213
	By Age/Sex: 5-9 Female		1,431
	By Age/Sex: 10-14 Female		1,386
	By Age/Sex: 15-19 Female		1,609
	By Age/Sex: 20-24 Female		1,865
	By Age/Sex: 25-49 Female		6,092
	By Age/Sex: 50+ Female		2,038
	Sum of Age/Sex disaggregates		31,207
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
	TX_RET_DSD Percent of		
TX_RET_DSD	adults and children known to be alive and on treatment 12	n/a	
	months after initiation of		



antiretroviral therapy	
Number of adults and	
children who are still alive	50
and on treatment at 12	30
months after initiating ART	
Total number of adults and	
children who initiated ART in	
the 12 months prior to the	
beginning of the reporting	
period, including those who	52
have died, those who have	
stopped ART, and those lost	
to follow-up	
Age/Sex: <5 Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	C
12 months after initiating	
ART)	
Age/Sex: 5-14 Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	2
12 months after initiating	
ART)	
Age/Sex: 15-19 Male	
(Numerator: Number of	
adults and children who are	C
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 20+ Male	
(Numerator: Number of	
adults and children who are	34
still alive and on treatment at	
12 months after initiating	



	1	
ART)		
Age/Sex: <5 Female		
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		0
12 months after initiating		
ART)		
Age/Sex: 5-14 Female		
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		1
12 months after initiating		
ART)		
Age/Sex: 15-19 Female		
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		0
12 months after initiating		
ART)		
Age/Sex: 20+ Female		
(Numerator: Number of		
adults and children who are		
still alive and on treatment at		13
12 months after initiating		
ART)		
Age/Sex: <5 Male		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		0
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 5-14 Male		2



(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male	
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
including those who have died, those who have stopped ART, and those lost to follow-up)	
died, those who have stopped ART, and those lost to follow-up)	
stopped ART, and those lost to follow-up)	
to follow-up)	
Age/Sex: 15-19 Male	
rigoroon. To To Wallo	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	1
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	34
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: <5 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	0
months prior to the beginning	
of the reporting period,	
including those who have	



	i	
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 5-14 Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		_
of the reporting period,		1
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 15-19 Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		_
of the reporting period,		1
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 20+ Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		13
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Numerator by Status:		
Pregnant		5
Numerator by Status:		0



	Breastfeeding		
	Denominator by Status:		_
	Pregnant		5
	Denominator by Status:		
	Breastfeeding		0
	TX_RET_TA Percent of		
	adults and children known to		
	be alive and on treatment 12	n/a	
	months after initiation of		
	antiretroviral therapy		
	Number of adults and		
	children who are still alive		7.705
	and on treatment at 12		7,785
	months after initiating ART		
	Total number of adults and		
	children who initiated ART in		
	the 12 months prior to the		
	beginning of the reporting		0.707
	period, including those who		9,737
	have died, those who have		
TX_RET_TA	stopped ART, and those lost		
	to follow-up		
	Age/Sex: <5 Male		
	(Numerator: Number of		
	adults and children who are		444
	still alive and on treatment at		414
	12 months after initiating		
	ART)		
	Age/Sex: 5-14 Male		
	(Numerator: Number of		
	adults and children who are		
	still alive and on treatment at		762
	12 months after initiating		
	ART)		
	Age/Sex: 15-19 Male		392



(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,212
Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	417
Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	754
Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	404
Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,430
Age/Sex: <5 Male	518



(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 2,758
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who ave stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
stopped ART, and those lost to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
to follow-up) Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
died, those who have stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
stopped ART, and those lost to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
to follow-up) Age/Sex: 20+ Male (Denominator: Total number of adults and children who
Age/Sex: 20+ Male (Denominator: Total number of adults and children who
(Denominator: Total number of adults and children who
of adults and children who
months prior to the beginning
of the reporting period,
including those who have



died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: <5 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	527
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 5-14 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	942
of the reporting period,	342
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	507
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Female	
(Denominator: Total number	3,043
of adults and children who	3,043
or addits and children who	



	1	1	1
	initiated ART in the 12		
	months prior to the beginning		
	of the reporting period,		
	including those who have		
	died, those who have		
	stopped ART, and those lost		
	to follow-up)		
	Numerator by Status:		
	Pregnant		
	Numerator by Status:		
	Breastfeeding		
	Denominator by Status:		
	Pregnant		
	Denominator by Status:		
	Breastfeeding		
	TX_VIRAL_DSD Percentage		
	of ART patients with an	,	
	undetectable viral load at 12	n/a	
	months after initiation of ART		
	Number of adult and		
	pediatric ART patients with a		
	viral load result documented		1,120
	in the patient medical record		
	within the past 12 months		
	Number of adults and		
TX_VIRAL_DSD	children on ART at least 6		4 400
	months whose medical		1,120
	records were reviewed		
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		0
	Age/Sex: 15-19 Male		0
	Age/Sex: 20+ Male		0
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0
_			



	Age/Sex: 5-14 Female		0
	Age/Sex: 15-19 Female		112
	Age/Sex: 20+ Female		1,008
	Results Category: Undetectable		
	Results Category: Detectable		
	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		115,674
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		144,664
TX_VIRAL_TA	Age/Sex: <1 Male		1,487
	Age/Sex: 1-4 Male		4,974
	Age/Sex: 5-14 Male		11,519
	Age/Sex: 15-19 Male		5,898
	Age/Sex: 20+Male		32,371
	Age/Sex: <1 Female		1,495
	Age/Ses: 1-4 Female		4,872
	Age/Sex: 5-14 Female		11,366
	Age/Sex: 15-19 Female		6,019
	Age/Sex: 20+ Female		35,673
	Result Category: Undetectable		104,113
	Result Category: Detectable		11,561
LAB_ACC_DSD	Number of PEPFAR-supported testing		8



	facilities (laboratories) that	
	are recognized by national,	
	regional, or international	
	standards for accreditation or	
	have achieved a minimal	
	acceptable level towards	
	attainment of such	
	accreditation	
	Number of	
	PEPFAR-supported testing	
	facilities with capacity to	23
LAR CAR DOD	perform clinical laboratory	20
LAB_CAP_DSD	tests	
	By clinical laboratories	23
	By Point-of-care testing sites	
	Percentage of laboratories	
	and POC testing sites that	
	perform HIV diagnostic	
	testing that participate and	
	successfully pass in an	
	analyte-specific proficiency	
	testing (PT) program	
	CD4: Number of laboratories	
	that achieve acceptable	
	successful passing criteria in	14
LAB_PT_TA	this PT program	
	CD4: Number of laboratories	
	that participate in this PT	14
	program	
	CD4: Number of laboratories	
	that perform this testing	14
	Early infant diagnostics:	
	Number of laboratories that	
	achieve acceptable	4
	successful passing criteria in	



t	his PT program	
E L	Early infant diagnostics: Number of laboratories that participate in this PT program	4
1	Early infant diagnostics: Number of laboratories that perform this testing	4
t I: E	HIV serologic/diagnostic resting: Number of aboratories that achieve acceptable successful passing criteria in this PT program	19
t I:	HIV serologic/diagnostic esting: Number of aboratories that participate n this PT program	19
t I:	HIV serologic/diagnostic resting: Number of aboratories that perform this resting	19
	HIV viral load: Number of aboratories that achieve acceptable successful bassing criteria in this PT program	11
l	HIV viral load: Number of aboratories that participate n this PT program	11
	HIV viral load: Number of aboratories that perform this esting	11
1	ΓΒ diagnostics (AFB microscopy): Number of	20



	Y.	1
laboratories that achieve		
acceptable successful		
passing criteria in this PT		
program		
TB diagnostics (AFB		
microscopy): Number of		20
laboratories that participate		20
in this PT program		
TB diagnostics (AFB		
microscopy): Number of		00
laboratories that perform this		20
testing		
TB diagnostics (Xpert		
MTB/RIF): Number of		
laboratories that achieve		
acceptable successful		16
passing criteria in this PT		
program		
TB diagnostics (Xpert		
MTB/RIF): Number of		40
laboratories that participate		16
in this PT program		
TB diagnostics (Xpert		
MTB/RIF): Number of		
laboratories that perform this		16
testing		
TB diagnostics		
(Culture/DST): Number of		
laboratories that achieve		
acceptable successful		1
passing criteria in this PT		
program		
TB diagnostics		
(Culture/DST): Number of		
laboratories that participate		1
in this PT program		
program	<u>I</u>	<u> </u>



	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		1
	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		1,008
	Number of viral load tests performed from adults and children on ART within the current reporting period		1,008
	Age/Sex: <1 Male		0
TX_UNDETECT_DSD	Age/Sex: 1-4 Male		0
	Age/Sex: 5-14 Male		0
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Male		
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 5-14 Female		0
	Age/Sex: 15-19 Female		101
	Age/Sex: 20+ Female		907
	Pregnant		
	Breastfeeding		
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		



	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		104,379
	Number of viral load tests performed from adults and children on ART within the current reporting period		115,980
	Age/Sex: <1 Female		1,347
TX_UNDETECT_TA	Age/Sex: <1 Male		1,350
	Age/Sex: 1-4 Female		4,405
	Age/Sex: 1-4 Male		4,489
	Age/Sex: 15-19 Female		5,430
	Age/Sex: 15-19 Male		5,320
	Age/Sex: 20+ Female		32,175
	Age/Sex: 20+ Male		29,205
	Age/Sex: 5-14 Female		10,262
	Age/Sex: 5-14 Male		10,396
	Breastfeeding		
	Pregnant		
	Test indication: Routine monitoring		104,379
	Test indication: Targeted monitoring		0



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7319	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
7320	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
7324	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
9915	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
9920	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
9924	Baylor University	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	11.2 2 6		Human		
10313	University of	University	Services/Centers	GHP-State	0
	Pennsylvania		for Disease		
			Control and		
			Prevention		
	Population				
11063	Services	NGO	U.S. Department	GHP-State	0
	International		of Defense		
	U.S. Department				
11577	of Defense	Other USG	U.S. Department	GHP-State	0
	(Defense)	Agency	of Defense		
			U.S. Department		
			of Health and		
	Johns Hopkins		Human		
12008	University	University	Services/Centers	GHP-State	0
	Bloomberg School		for Disease		
	of Public Health		Control and		
			Prevention		
			U.S. Department		
			of Health and		
		Host Country	Human		
12817	Government of	Government	Services/Centers	GHP-State	0
	Botswana	Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
13091	E L C.		of Health and		
	Education Development Center	evelopment NGO	Human	OUD OU	
			Services/Centers	GHP-State	0
		Center		for Disease	
			Control and		



			Prevention		
13480	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	o
13566	Tebelopele Voluntary Counseling and Testing	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	707,640
13646	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	3,325,000
13669	Project Concern International	NGO	U.S. Agency for International Development	GHP-State	516,618
14487	Association of Schools of Public Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14707	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	75,000
14790	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
16714	Abt Associates	Private Contractor	U.S. Agency for	GHP-State	0



			1		
			International		
			Development		
	University		U.S. Agency for		
16731	Research	Private Contractor		GHP-State	1,500,000
	Corporation, LLC		Development		
			U.S. Department		
			of Health and		
	Botswana Red		Human		
16736	Cross	NGO	Services/Centers	GHP-State	500,000
	01033		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	The Task Force for Global Health, Inc. /Tephinet	NGO	Human	GHP-State	0
16737			Services/Centers		
			for Disease		
			Control and		
			Prevention		
17005	U.S. Peace Corps	Other USG	U.S. Peace Corps	GHP-State	120,000
17003	U.S. I eace Corps	Agency	O.O. 1 eace Corps	OTIT -State	120,000
			U.S. Department		
			of Health and		
	African Society for		Human		
17007	Laboratory	NGO	Services/Centers	GHP-State	450,000
	Medicine		for Disease		
			Control and		
			Prevention	1	
			U.S. Department		
	University of Maryland		of Health and		
		University	Human		
17274				GHP-State	4,709,042
			for Disease		
			Control and		
			Prevention		
17275	African	NGO	U.S. Department	GHP-State	280,000



					1
	Comprehensive		of Health and		
	HIV/AIDS		Human		
	Partnerships		Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	American		Human		
17278	International	NGO	Services/Health	GHP-State	0
	Health Alliance		Resources and		
	Twinning Center		Services		
			Administration		
			U.S. Department		
			of Health and		
	American		Human		
17282	Association of	NGO	Services/Centers	GHP-State	О
	Blood Banks		for Disease		
			Control and		
			Prevention		
17321	TBD	TBD	Redacted	Redacted	Redacted
	University of North				
	Carolina at		U.S. Agency for		
17322	Chapel Hill,	University	International	GHP-State	680,000
	Carolina	,	Development		,
	Population Center		,		
	KNCV		U.S. Agency for		
17323	Tuberculosis	NGO	International	GHP-State	700,000
	Foundation		Development		
17415	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
17544	JHPIEGO	University	of Defense	GHP-State	0
17845	TDD	TBD	Redacted	Redacted	Redacted
17043	TBD	. = =			
17846	TBD	TBD	Redacted	Redacted	Redacted



	Pennsylvania		of Health and		
			Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
17861	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Agency for		
17862	FHI 360	NGO	International	GHP-State	1,867,010
			Development		
			U.S. Agency for		
17863	FHI 360	NGO	International	GHP-State	6,522,387
			Development		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7319	Mechanism Name: Supply Chain Management System (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain I	Management
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

budget Code information		
Mechanism ID:	7319	



Mechanism Name: Prime Partner Name:	117	Supply Chain Management System (SCMS) Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXD	0	0	

(No data provided.)

Mechanism ID: 7320	Mechanism Name: RPSO laboratory construction projects
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support	: Office/Frankfurt
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Baaget Coac Illioni	sudget Code information			
Mechanism ID:	7320	320		
Mechanism Name:	RPSO laboratory consti	uction projects		
Prime Partner Name:	Regional Procurement	Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HMBL	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	0	0	

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7324	Mechanism Name: Botswana Civil Society Strengthening Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code information		
Mechanism ID:	7324	



Mechanism Name: Prime Partner Name:	, , ,		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

mpromorning moontains a country		
Mechanism ID: 9915	Mechanism Name: Capacity building assistance for global HIV/AIDS microbiological labs	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: American Society for Microbiology		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Applied Pipeline Amount: 225,000	
Funding Source	Funding Amount
GHP-State	450,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Baagot Ooao iinoiiii	ation		
Mechanism ID:	9915		
Mechanism Name:	Capacity building assistance for global HIV/AIDS microbiological labs		
Prime Partner Name:	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	450,000	0

Implementing Mechanism Indicator Information

(No data provided.)

implementing mechanism betans		
Mechanism ID: 9920	Mechanism Name: Partnership to assist PEPFAR build quality laboratory capacity	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement		
Prime Partner Name: Association of Public Health Laboratories		



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 200,000 Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	200,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	9920		
Mechanism Name:	Partnership to assist PEPFAR build quality laboratory capacity		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9924	Mechanism Name: Pediatric HIV/AIDS Care and Outreach	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Baylor University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID:	9924
Mechanism Name:	Pediatric HIV/AIDS Care and Outreach
Prime Partner Name:	Baylor University



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10313	Mechanism Name: Technical assistance for training health care providers - University of Pennsylvania
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Pennsylva	ania
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	o

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	10313 Technical assistance for training health care providers - University of Pennsylvania University of Pennsylvania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 11063	Mechanism Name: Prevention OP,CIRC and HVCT
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

budget Code information				
Mechanism ID:	11063			
Mechanism Name:	Prevention OP,CIRC and	Prevention OP,CIRC and HVCT		
Prime Partner Name:	Population Services International			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Prevention	CIRC 0 0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Prevention	HVOP	0	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11577	Mechanism Name: Department of Defense (DOD)	
Funding Agency: DOD	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of Defense (I	Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	11577		
Mechanism Name:	Department of Defense (DOD)		
Prime Partner Name:	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12008	Mechanism Name: Expansion of Safe Male Circumcision Services to Prevent HIV	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

- 2				
	Mechanism ID:	12008		
	Mechanism Name:	Expansion of Safe Male	Circumcision Services to	o Prevent HIV
	Prime Partner Name:	Johns Hopkins Univers	ity Bloomberg School of	Public Health
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 12817	Mechanism Name: Prevention, Strengthening Health and SI Systems and Access To Quality HIV/AIDS Services Through Support Programs Conducted By The Government Of Botswana
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Government of Botsw	vana
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	1
G2G: Yes	Managing Agency: HHS/CDC
Total All Funding Sources: 0	
Applied Pipeline Amount: 2,172,087	



Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID: Prevention, Strengthening Health and SI Systems and Access To Mechanism Name: Quality HIV/AIDS Services Through Support Programs Conducted By The Prime Partner Name: Government Of Botswana Government of Botswana			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



(No data provided.)

Implementing Mechanism Details

implementing wechanism betails		
Mechanism ID: 13091	Mechanism Name: Implementing the Living Life Skills Curriculum in Botswana	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Education Development Center		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	О

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Mechanism ID:	13091		
Mechanism Name:	Implementing the Living Life Skills Curriculum in Botswana		
Prime Partner Name:	Education Development Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 13480	Mechanism Name: Building Local Capacity for Delivery of Health Services in Southern Africa	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Management Sciences for Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0 Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	Building Local Capacity for Delivery of Health Services in Southern Me: Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 13566	Mechanism Name: Expanding Access and Enhancing Quality of Integrated HTC Services	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Tebelopele Voluntary Counseling and Testing		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 707,640 Applied Pipeline Amount: 1,790,000		
Funding Source	Funding Amount	
GHP-State	707,640	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	197,640	
	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention	
	Collection and use of strategic information on SWs and clients	

Key Issues

(No data provided.)

Mechanism ID:	13566		
Mechanism Name:	Expanding Access and Enhancing Quality of Integrated HTC Services		
Prime Partner Name:	Tebelopele Voluntary Counseling and Testing		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	510,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	197,640	0

(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 13646	Mechanism Name: International Training and Education Center for Health (ITECH)	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,325,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,325,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues



Budget Code Information

Budget Code Inform	ation		
Mechanism ID:	13646		
Mechanism Name:	International Training a	nd Education Center for H	Health (ITECH)
Prime Partner Name:	University of Washington	on	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	600,000	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	700,000	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	375,000	C
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	650,000	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	900,000	C

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

implementing incomanion because	
Mechanism ID: 13669	Mechanism Name: OVC-Gender
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 516,618 Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	516,618

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID:	13669
Mechanism Name:	OVC-Gender
Prime Partner Name:	Project Concern International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	516,618	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14487	Mechanism Name: African Health Workforce Project
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Schoo	ls of Public Health
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	A
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 94,240	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



Key Issues

(No data provided.)

Budget Code Information

	Baagot Goao iinoiini			
	Mechanism ID:	14487		
١	Mechanism Name:	African Health Workford	ce Project	
	Prime Partner Name:	Association of Schools	of Public Health	
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 14707	Mechanism Name: Ambassador"s PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of S	tate
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 75,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	75,000



(No data provided.)

Cross-Cutting Budget Attribution(s)

Cross-Cutting Budget Attribution(s)		
Economic Strengthening	25,000	
Education	51,194	
Renovation	13,100	
Gender: GBV	25,000	
Focus Area:	GBV Prevention	
Sub Area:	Capacity building	
Key Populations: FSW	25,000	
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention	
Focus Area:	Training of health workers and community outreach workers	
Construction	24,999	

Key Issues

(No data provided.)

Mechanism ID:	14707 Ambassador"s PEPFAR Small Grants Program		
	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	75,000	0



(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 14790	Mechanism Name: Public Affairs/Public Diplomacy (PA/PD) Outreach	
Funding Agency: State/AF	Procurement Type: USG Core	
Prime Partner Name: U.S. Department of State		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	150,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Education	50,000
Economic Strengthening	10,000

Key Issues



(No data provided.)

Budget Code Information

므	Bauget Code information			
	Mechanism ID:	14790		
	Mechanism Name:	Public Affairs/Public Diplomacy (PA/PD) Outreach		
	Prime Partner Name:	e Partner Name: U.S. Department of State		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16714	Mechanism Name: Health Finance and Governance Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Abt Associates		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 405,000	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code information			
Mechanism ID:	16714		
Mechanism Name:	ame: Health Finance and Governance Project		
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 16731	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,500,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	16731		
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST) Project		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 16736	Mechanism Name: HIV care and treatment services in the Dukwi refugee camp	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	



Prime Partner Name: Botswana Red Cross	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No Managing Agency:	

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	500,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Badgot Godo Information			
Mechanism ID:	16736		
Mechanism Name:	HIV care and treatment services in the Dukwi refugee camp		
Prime Partner Name:	Botswana Red Cross		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

(No data provided.)

Mechanism ID: 16737	Mechanism Name: Building Capacity of the Public Health System to Improve Population Health through National, Nonprofit Organizations	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: The Task Force for Global Health, Inc. /Tephinet		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Code information			
Mechanism ID: Mechanism Name:	16737 Building Capacity of the Public Health System to Improve Population Health through National, Nonprofit Organizations		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17005	Mechanism Name: Peace Corps HIV/AIDS Activities	
Funding Agency: PC	Procurement Type: Grant	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 120,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	120,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	80,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building

Key Issues

(No data provided.)

Budget Code Information

_ = = = = = = = = = = = = = = = = = = =			
Mechanism ID:	17005		
Mechanism Name:	Peace Corps HIV/AIDS Activities		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	120,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

impromonting moonamen bottone		
Mechanism ID: 17007	Mechanism Name: Development of Lab Network & Society	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: African Society for Laboratory Medicine		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 450,000 Applied Pipeline Amount: 160,000	
Funding Source	Funding Amount
GHP-State	450,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID:	17007
Mechanism Name:	Development of Lab Network & Society
Prime Partner Name:	African Society for Laboratory Medicine



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17274	Mechanism Name: Capacity Building and Training	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Maryland		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,709,042	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,709,042

Sub Partner Name(s)



Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information			
Mechanism ID: 17274			
Mechanism Name:	Capacity Building and Training		
Prime Partner Name:	University of Maryland		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	НВНС	1,320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	380,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,629,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	380,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17275	Mechanism Name: Voluntary Medical Male Circumcision
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: African Comprehensive HIV/AIDS Partnerships		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		

Total All Funding Sources: 280,000	
Applied Pipeline Amount: 1,910,000	
Funding Source	Funding Amount
GHP-State	280,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17275		
Mechanism Name:	Voluntary Medical Male Circumcision		
Prime Partner Name:	African Comprehensive HIV/AIDS Partnerships		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	CIRC	280,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17278	Mechanism Name: Twinning	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: American International Health Alliance Twinning Center		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Dauget Gode Intermation			
Mechanism ID:	17278		
Mechanism Name:	Twinning		
Prime Partner Name:	American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

(No data provided.)

Implementing Mechanism Details

implementing incondition bottom		
Mechanism ID: 17282	Mechanism Name: Blood Safety	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: American Association of Blood Banks		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)



Key Issues

(No data provided.)

Budget Code Information

Budget Joue information			
Mechanism ID:	17282		
Mechanism Name:	Blood Safety		
Prime Partner Name:	American Association of Blood Banks		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HMBL	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17321	TBD: Yes
REDACTED	

Mechanism ID: 17322	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 680,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	680,000

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	600,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	80,000
Focus Area:	Increase gender-equitable access to income and
	productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Monitoring and Evaluation



Key Issues

(No data provided.)

Budget Code Information

	Budget Code Information			
	Mechanism ID:	17322		
	Mechanism Name:	MEASURE Evaluation Phase IV		
	Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
İ	Prevention	HVOP	680,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

inplementing meenament betane		
Mechanism ID: 17323	Mechanism Name: Challenge TB	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: KNCV Tuberculosis Foundation		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 700,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	700,000

Sub Partner Name(s)



Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
riuman Resources for Fleatin	330,000

Key Issues

(No data provided.)

Budget Code Information

ים	Budget Code information			
	Mechanism ID:	17323		
	Mechanism Name:	Challenge TB		
	Prime Partner Name:	KNCV Tuberculosis Foundation		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Care	HVTB	700,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17415	TBD: Yes
REDACTED	

Mechanism ID: 17544	Mechanism Name: Strengthening HIV/AIDS Clinical Prevention within the Botswana Defense Force",
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 1,000,000	
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID: Mechanism Name:	Strengthening HIV/AIDS Clinical Prevention within the Botswana Defense Force".		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17845	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17846	TBD: Yes
REDACTED	

Mechanism ID: 17847	Mechanism Name: Capacity Building through Training and Mentoring for TB/HIV	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Pennsylvania		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,100,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,100,000



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Dadget Code Information			
Mechanism ID:	17847		
Mechanism Name:	Capacity Building through Training and Mentoring for TB/HIV		
Prime Partner Name:	University of Pennsylvania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17861	TBD: Yes
REDACTED	

Mechanism ID: 17862	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,867,010	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,867,010

(No data provided.)

Cross-Cutting Budget Attribution(s)

stoco datting baaget / tti ibation(c)	
Key Populations: FSW	1,400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	467,010
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information

Key Issues

(No data provided.)



Mechanism ID: Mechanism Name: Prime Partner Name:	LINKAGES		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	580,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	457,010	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	830,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17863	Mechanism Name: Advancing Partners and Communities	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,522,387	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	6,522,387

Sub Partner Name(s)



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Budget Gode Inform	Budget Code information						
Mechanism ID:	17863						
Mechanism Name:	Advancing Partners and Communities						
Prime Partner Name:	FHI 360	HI 360					
Strategic Area	Budget Code	Budget Code Planned Amount On Hold Amour					
Care	НВНС	3,875,000	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Care	HVTB	800,000	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Care	PDCS	800,000	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Prevention	HVCT	350,000	0				
Strategic Area	Budget Code	Planned Amount	On Hold Amount				
Prevention	HVOP	697,387	0				

Implementing Mechanism Indicator Information





Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		82,766		82,766	0
ICASS		432,397		432,397	0
Institutional Contractors		212,074		212,074	0
Management Meetings/Professio nal Development		146,688		146,688	0
Non-ICASS Administrative Costs		425,011		425,011	0
Staff Program Travel		117,929		117,929	0
USG Staff Salaries and Benefits		1,654,406		1,654,406	0
Total	0	3,071,271	0	3,071,271	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		0		0	800
ICASS		0		0	25,200



Non-ICASS Administrative Costs		0		0	1,600
Staff Program Travel				0	11,500
USG Staff Salaries and Benefits		0		0	55,900
Total	0	0	0	0	95,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		84,700		84,700	0
Computers/IT Services		790,211		790,211	0
ICASS		1,472,189		1,472,189	0
Institutional Contractors		0		0	0
Management Meetings/Professio nal Development		40,000		40,000	0
Non-ICASS Administrative Costs		642,388		642,388	0
Staff Program Travel		340,536		340,536	0
USG Staff Salaries and Benefits	2,196,250	955,726		3,151,976	0
Total	2,196,250	4,325,750	0	6,522,000	0



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		14,960		14,960	0
Management Meetings/Professio nal Development		14,000		14,000	0
Non-ICASS Administrative Costs		25,410		25,410	0
Staff Program Travel		14,000		14,000	0
USG Staff Salaries and Benefits		117,545		117,545	0
Total	0	185,915	0	185,915	0

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		126		126	0
Institutional Contractors				0	O
Non-ICASS Administrative Costs		63,183		63,183	0
Peace Corps Volunteer Costs	0	1,284,837	0	1,284,837	500,000



Total	0	1,730,091	0	1,730,091	500,000
and Benefits		047,201		347,231	J
USG Staff Salaries		347,291		347,291	0
Staff Program Travel		34,654		34,654	0